© 2026 GlobalCapital, Derivia Intelligence Limited, company number 15235970, 161 Farringdon Rd, London EC1R 3AL. All rights reserved.

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement | Event Participant Terms & Conditions | Cookies

Equity

More articles

More articles

More articles

  • A large positive move in stock prices in the past three weeks has buoyed many market commentators, but equities bankers and investors are concerned that equity valuations still do not reflect the severity of the economic effects of the Covid-19 pandemic. If first quarter results or a worsening of the virus are bad enough to drive markets lower still, sufficient harm could be done to investor sentiment to slam shut a vital issuance window for companies desperate to raise cash.
  • China’s government has won plaudits for its response to the Covid-19 coronavirus. That praise should extend to its capital markets.
  • The China Securities Regulatory Commission (CSRC) has penalised two Star market companies for failing to make sufficient risk disclosures in their IPO documents. The duo were among the first batch of 25 companies to list on the Star board.
  • Akesobio, a Chinese biopharmaceutical firm, has launched an online-only roadshow for its up to HK$2.58bn ($332.9m) IPO amid numerous country-wide lockdowns globally to combat the Covid-19 coronavirus pandemic.
  • Bronte Capital’s funds posted bumper gains in March. The hedge fund founded by the famous Australian short seller John Hempton benefitted from puts and shorts purchased before other investors panicked about the spread of coronavirus.
  • Supermarket Income Reit, the UK real estate investment trust focused on supermarkets, has unveiled a £75m fundraising to finance new investment opportunities that may arise from the Covid-19 crisis, which had caused UK grocers to be inundated with demand.
shared comment list